Archived Newsletters
-
04.19.24 -- Outsourcing Through An Industry-Government Battle
4/19/2024
04/19/24 Outsourced Pharma Newsletter
-
04.18.24 -- Process Development: Stuck In The Middle With You
4/18/2024
04/18/24 Outsourced Pharma Newsletter
-
04.17.24 -- Leverage Innovative Assays And Monitoring To Improve mAb Production
4/17/2024
04/17/24 Outsourced Pharma Newsletter
-
04.17.24 -- A Guide To Proactive Supplier Management In The Pharma/Biotech Industry
4/17/2024
04/17/24 Outsourced Pharma Newsletter
-
04.16.24 -- Successfully Navigate The Path To IND Submission
4/16/2024
04/16/24 Outsourced Pharma Newsletter
-
04.16.24 -- Why Are Cell-Therapy Outsourcers Unhappy? Investors Know
4/16/2024
04/16/24 Outsourced Pharma Newsletter
-
04.15.24 -- Leverage A Viral Vector Production Platform To Improve Efficiency
4/15/2024
04/15/24 Outsourced Pharma Newsletter
-
04.15.24 -- Getting To Know MAM, The New Quality Control Strategy On The Block
4/15/2024
04/15/24 Outsourced Pharma Newsletter
-
04.12.24 -- Impacts Of The Inflation Reduction Act (IRA)
4/12/2024
04/12/24 Outsourced Pharma Newsletter
-
04.11.24 -- From Ally To Adversary: BIO's Swift Rebuke Of WuXi
4/11/2024
04/11/24 Outsourced Pharma Newsletter
This website uses cookies to ensure you get the best experience on our website. Learn more